4-溴-N-(2-吡咯烷-1-基乙基)苯磺酰胺 | 209968-27-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-N-(2-吡咯烷-1-基乙基)苯磺酰胺
• 英文名称: 4-bromo-N-(2-pyrrolidin-1-ylethyl)benzenesulfonamide
• 英文别名: 4-bromo-N-(2-pyrrolidin-1-yl-ethyl)-benzenesulfonamide
• CAS: 209968-27-4
• 化学式: C₁₂H₁₇BrN₂O₂S
• mdl: MFCD02556611
• 分子量: 333.249
• InChiKey: DIYRIYJMMLUTQP-UHFFFAOYSA-N

物化性质

• 沸点：
  437.4±55.0 °C(Predicted)
• 密度：
  1.458±0.06 g/cm3(Predicted)
• 溶解度：
  46.9 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  4-溴-N-(2-吡咯烷-1-基乙基)苯磺酰胺 在 palladium diacetate 、 palladium 10% on activated carbon 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 potassium tert-butylate 、 氢气 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 2-chloro-N-(2-(4-(2-pyrrolidin-1-yl-ethylsulfamoyl)-phenylamino)-pyrimidin-5-yl)-5-(3-trifluoromethyl-benzoylamino)-benzamide
  参考文献：
  名称：

  WO2008/8234

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(2-氨乙基)吡咯烷 、 4-溴苯磺酰氯 在 碳酸氢钠 作用下， 以 氯仿 为溶剂， 反应 15.0h， 以88%的产率得到4-溴-N-(2-吡咯烷-1-基乙基)苯磺酰胺
  参考文献：
  名称：

  Substituted Halogenated Arylsulfonamides:  A New Class of σ Receptor Binding Tumor Imaging Agents

  摘要：

  The discovery of a series of novel halogenated arylsulfonamides (HAS) as new sigma receptor binding tumor imaging agents is described. Several substituted halogenated sulfonamides have been prepared and characterized. Target compounds were examined for their affinity for sigma(1) and sigma(2) receptor subtypes using guineapig brain membranes and rat liver membranes, respectively. A number of substituted halogenated sulfonamides displayed subnanomolar affinities for sigma(1) sites add low nanomolar affinities for sigma(2) subtype receptors. A limited structure-activity relationship study of this chemical series is discussed. The radioiodination (I-125) of one congener member (4-[I-125]iodo-N-[2-(1'-piperidinyl)ethyl]benzenesulfonamide 4-[I-125]IPBS) was accomplished in high yields. The in vitro competition binding studies of 4-[I-125]IPBS in guinea pig brain membranes with sigma receptor binding ligands confirmed its sigma pharmacology. The rank order of potency was BD1008 [N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)- ethylamine)> 4-IPBS > haloperidol > (+)-pentazocine > DTG (1,3-di-o-tolylguanidine) > (-)-pentazocine. The inhibition constants (IC50) were 0.70, 1.46, 6.28, 10.4, 87.2, and 152 nM, respectively, and are consistent with labeling of sigma(1) receptors. The tumor imaging potential of 4-[I-125]IPBS was studied in C57 black mice bearing B16 melanoma xenograft. A high tumor uptake of 4-[I-125]IPBS was observed (7.40% ID/g) at 1 h postinjection. The wash out of activity from the tumor was slow at 6 h postinjection (7.22% ID/g). The tumor also had the highest amount of radioactivity (1.54% ID/g) at 24 h postinjection. These results demonstrate that radiohalogenated benzenesulfonamides could be a potentially useful class of compounds in nuclear oncologic scintigraphy.

  DOI：

  10.1021/jm9800447

文献信息

• [EN] PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS<br/>[FR] COMPOSÉS DE PYRROLOPYRIMIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DES JANUS KINASES
  申请人：TARGEGEN INC

  公开号：WO2009049028A1

  公开（公告）日：2009-04-16

  Provided herein are pyrrolopyrimidine compounds of Formula (I) wherein R1 is a heteroaryl containing at least one S atom, and optionally substituted on a ring carbon by one, two, or three substituents each independently selected from the group consisting of : halo, hydroxyl, nitro, formyl, formamido, cyano, sulfonyl, carboxy, amino, amido, acylamino, carbamoyl, sulphamoyl, alkyl, alkenyl, CF3, ureido, alkynyl, alkoxy, alkanoyl, alkoxycarbonyl, carbaldehyde oxime, N -alkylsulphamoyl, N-alkylcarbamoyl, -OR13R11 or -R13R11; R2 is phenyl or pyridinyl, wherein R2 optionally substituted on a ring carbon by one, two, or three substituents each indenpendently selected from the group consisting of : halo, hydroxyl, cyano, nitro, formyl, formamido, carboxy, sulfonyl, amino, amido, -N- alkyl -amino, carbamoyl, sulphamoyl, CF3, ureido, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkoxycarbonyl, N-alkylsulphamoyl, N-alkylcarbamoyl, -OR11, -OR12R11, or -R12R11; and methods of making and using the same. Such compounds may be used in inflammatory or myeloproliferative disorders. The disclosure also provides for treating cancer.

  本文提供了通式(I)的吡咯并嘧啶化合物，其中R1是含有至少一个硫原子的杂芳基，并且任选地在芳环碳上被一个、两个或三个取代基取代，这些取代基独立地从以下基团中选择：卤素、羟基、硝基、甲酰基、甲酰胺基、氰基、磺酰基、羧基、氨基、酰胺基、酰氨基、氨基甲酰基、磺酰胺基、烷基、烯基、CF3、脲基、炔基、烷氧基、烷酰基、烷氧羰基、羧醛肟、N-烷基磺酰胺基、N-烷基氨基甲酰基、-OR13R11或-R13R11；R2是苯基或吡啶基，其中R2任选地在环碳上被一个、两个或三个取代基取代，这些取代基独立地从以下基团中选择：卤素、羟基、氰基、硝基、甲酰基、甲酰胺基、羧基、磺酰基、氨基、酰胺基、-N-烷基-氨基、氨基甲酰基、磺酰胺基、CF3、脲基、烷基、烯基、炔基、烷氧基、烷酰基、烷氧羰基、N-烷基磺酰胺基、N-烷基氨基甲酰基、-OR11、-OR12R11或-R12R11；以及其制备和使用方法。这些化合物可用于炎症性或骨髓增生性疾病。该披露还提供了用于治疗癌症的方法。
• Benzotriazine inhibitors of kinases
  申请人：Noronha Glenn

  公开号：US20050245524A1

  公开（公告）日：2005-11-03

  The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.

  该发明提供了具有化学式（I）的苯并三唑化合物。该发明的苯并三唑化合物能够抑制激酶，如Src激酶家族成员，以及其他特定的受体和非受体激酶。
• Bi-aryl meta-pyrimidine inhibitors of kinases
  申请人：Noronha Glenn

  公开号：US20070259904A1

  公开（公告）日：2007-11-08

  The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供了具有一般结构（A）的联苯基间吡嘧啶化合物。本发明的吡嘧啶化合物能够抑制激酶，如Jak激酶家族成员以及其他特定的受体和非受体激酶。
• Arylamines for the treatment of conditions associated with gsk-3
  申请人：Berg Stefan

  公开号：US20060052396A1

  公开（公告）日：2006-03-09

  The present invention relates to new compounds of formula (I) wherein Z, Y, X, P, Q, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , A, m and n are defined as in any one of claims 1 to 3, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds for the treatment of conditions associated with glycogens synthase kinase-3 (GSK3).

  本发明涉及具有公式（I）的新化合物，其中Z、Y、X、P、Q、R、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A、m和n的定义如权利要求1至3中的任意一项，以及制备它们的过程和其中制备的新中间体，含有所述治疗活性化合物的制药配方以及使用所述活性化合物治疗与糖原合酶激酶-3（GSK3）相关的疾病的方法。
• Pyrimidine inhibitors of kinases
  申请人：Cao Jianguo

  公开号：US20060247250A1

  公开（公告）日：2006-11-02

  The invention provides pyrimidine compounds having formula A. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供了具有A式的嘧啶化合物。本发明的嘧啶化合物能够抑制激酶，例如Src激酶家族成员和各种其他特定的受体和非受体激酶。